Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18948164 | 0.88 | KMT2A (0.40) | KMT2AGAAMEN1TSHRALDH1A1 | |
| SCHEMBL17931141 | 0.87 | KMT2A (0.39) | KMT2AGAAMEN1TSHRALDH1A1 | |
| SCHEMBL698553 | 0.82 | KMT2A (0.47) | KMT2AGAAMEN1TSHRALDH1A1 | |
| SCHEMBL1939153 | 0.82 | KMT2A (0.71) | KMT2AGAAMEN1TSHRALDH1A1 | |
| SCHEMBL7470898 | 0.81 | GAA (0.46) | KMT2AGAAMEN1TSHRALDH1A1 | |
| SCHEMBL7473740 | 0.81 | KMT2A (0.45) | KMT2AGAAMEN1TSHRALDH1A1 | |
| SCHEMBL27839363 | 0.81 | TSHR (0.48) | KMT2AGAAMEN1TSHRALDH1A1 | |
| SCHEMBL6501569 | 0.80 | TSHR (0.71) | KMT2AGAAMEN1TSHRALDH1A1 | |
| SCHEMBL9244396 | 0.80 | KMT2A (0.49) | KMT2AGAAMEN1TSHRALDH1A1 | |
| SCHEMBL27839267 | 0.80 | KMT2A (0.44) | KMT2AGAAMEN1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579328-B2 | Preparation from a sterically hindered nitroxy compound and a diazonium salt of an aromatic amine in the presence of a transition metal catalyst | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | claimed |
| EP-1278733-A1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED ARYLOXYAMINES | Ciba SC Holding AG (CH) | 2003-01-29 | — | — | EP | claimed |
| US-20020007585-A1 | Transition-metal-catalyzed process for the preparation of sterically hindered N-substituted aryloxyamines | CIBA SPECIALTY CHEMICALS CORP. | 2002-01-24 | — | — | US | claimed |
| WO-2001083455-A1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED ARYLOXYAMINES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2001-11-08 | — | — | WO | claimed |
| US-6579328-B2 | Preparation from a sterically hindered nitroxy compound and a diazonium salt of an aromatic amine in the presence of a transition metal catalyst | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| EP-1278733-A1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED ARYLOXYAMINES | Ciba SC Holding AG (CH) | 2003-01-29 | — | — | EP | disclosed |
| US-20020007585-A1 | Transition-metal-catalyzed process for the preparation of sterically hindered N-substituted aryloxyamines | CIBA SPECIALTY CHEMICALS CORP. | 2002-01-24 | — | — | US | disclosed |
| WO-2001083455-A1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED ARYLOXYAMINES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007585-A1 | Transition-metal-catalyzed process for the preparation of sterically hindered N-substituted aryloxyamines | SOD1, NNMT, TYR | KMT2A 392/4885GAA 800/4885MEN1 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.